Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...
Andrew Dudum, the CEO of Hims & Hers Health Inc. (NYSE:HIMS), recently sold shares worth approximately $815,029, according to ...
Dakota Wealth Management cut its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 13.4% during the fourth ...
Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...
Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...
Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...
In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 9.60% over the last five trades and -10.88% over the past 30 trades. This represents a notable shift ...
Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Hims & Hers Health, Inc. (HIMS) closed at $29.72 in the latest trading session, marking a -0.3% move from the prior day. This move lagged the S&P 500's daily gain of 0.61%. Elsewhere, the Dow ...